The spectrum of differential diagnosis of acquired demyelinating disorders of the central nervous system has been recently broadened. There is now growing evidence that supports anti-myelin oligodendrocyte antibodies associated demyelination as a distinct disease entity, with some clinical characteristics that somehow overlap those of Multiple Sclerosis (MS) and anti-AQP4+ Neuromyelitis Optica Spectrum Disorders (AQP4+NMOSD) but different pathogenesis and treatment strategies.
The clinical spectrum of anti-MOG associated acquired demyelinating disorders: Three case-reports / Bellinvia A.; Pasto L.; Razzolini L.; Fratangelo R.; Prestipino E.; Fonderico M.; Tudisco L.; Amato M.P.. - In: MULTIPLE SCLEROSIS AND RELATED DISORDERS. - ISSN 2211-0348. - ELETTRONICO. - 33:(2019), pp. 51-54. [10.1016/j.msard.2019.05.006]
The clinical spectrum of anti-MOG associated acquired demyelinating disorders: Three case-reports
Bellinvia A.;Razzolini L.;Fratangelo R.;Prestipino E.;Fonderico M.;Tudisco L.;Amato M. P.
2019
Abstract
The spectrum of differential diagnosis of acquired demyelinating disorders of the central nervous system has been recently broadened. There is now growing evidence that supports anti-myelin oligodendrocyte antibodies associated demyelination as a distinct disease entity, with some clinical characteristics that somehow overlap those of Multiple Sclerosis (MS) and anti-AQP4+ Neuromyelitis Optica Spectrum Disorders (AQP4+NMOSD) but different pathogenesis and treatment strategies.
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
